Rare disease leader Position Sobi as a global biopharma specializing in rare diseases with a strong footprint in Europe and North America. Leverage their focus to identify co-development, licensing, or distribution partnerships for rare disease therapies, particularly in hemophilia and kidney disease areas.

Financial scale Revenue range indicates substantial market presence but potential for expansion. Target opportunities to introduce complementary therapies, patient support programs, and payer-focused access strategies to maximize market penetration and accelerate adoption.

Patient engagement Award-winning patient engagement initiatives (Unite4Rare) signal openness to collaboration with patient groups and researchers. Propose partnerships for real-world data generation, patient-centric trial design, and value-based outcomes to strengthen evidence generation and market access.

Research & data focus Active data presentation at major conferences and World Kidney Day documentary launch indicate emphasis on transparent data and advocacy. Develop opportunities around real-world evidence studies, post-marketing surveillance collaborations, and digital health tools to support patients and clinicians.

Expansion potential Global footprint and ongoing participation in international forums (EHA, ERA, Euronews Health Summit) suggest readiness for geographic and indication expansion. Explore partnerships for regional commercialization, supply chain scaling, and cross-border regulatory strategies.